Irritable Bowel Syndrome with Constipation Drugs Market By Drug Type (Lubiprostone, Linaclotide, Stimulant Laxatives, Osmotic Laxatives,) and By Prescription Type (Prescribed, Over the Counter Drugs) - Growth, Future Prospects, and Competitive Analysis, 2018 -2026

Irritable bowel syndrome (IBS) is defined as persistent abdominal discomfort and pain occurring with changed bowel habits. This condition is classified into three types centered upon the prevalent bowel habits; IBS with diarrhea (IBS-D), IBS with constipation (IBS-C), and IBS with mixed presentations (IBS-M). It is among the most common gastrointestinal disorders, with a worldwide prevalence of approximately 11%. As of 2014, more than 30 million individuals over age 19 suffered from IBS across key national markets, namely the U.S., U.K., France, Italy, Germany, Japan, and Spain. The IBS market is observed to be underpenetrated and hence is deemed attractive for pharmaceutical manufacturers in the GI drugs market. The majority of IBS patients are women, and one-third of IBS patients experience constipation as a primary syndrome. Awareness about the attractiveness of the market potential and a growing understanding of disease pathophysiology render growth potential and further evolution of the IBS-C drugs market.

This report on global irritable bowel syndrome with constipation (IBS-C) drugs evaluates the current market scenario. In addition, it predicts future market trends for the commercialized and pipeline drugs for IBS-C treatment for the period from 2016 to 2026. IBS is among the most commonly prevalent gastrointestinal diseases for which the exact cause is not determined. However, the recent developments in research on this issue have led to the introduction of several novel disease treatment and management solutions.

For this study, the global irritable bowel syndrome with constipation drugs market was studied for two major segmentations: drug type and prescription type. These segments were further classified -for in-depth analysis as follows:

Market size and forecast analysis of the above-mentioned segments were evaluated for 2016-2026. Additionally, compounded annual growth rates (CAGRs) for the segments mentioned above have been provided for 2018 to 2026, keeping 2017 as the base year. 

In addition, the report also comprehends qualitative factors such as market restraints, drivers, and opportunities. This information would give an overall outlook on the current and future market dynamics. Understanding the market dynamics would enable emerging market players to strategize their products with a better understanding of the market. The IBS-C drugs market has a narrow competitive pool with few market players having target therapies for IBS-C. An understanding on the competitive landscape has been incorporated in this report, along with company profiles of the key market players. The company profiles have been included with information pertaining to financial information, product portfolio, recent news, and general company information. The companies profiled are Abbott Laboratories, Inc., Ardelyx. Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Fresenius Kabi AG, Ironwood Pharmaceuticals, Inc., Sanofi, SK Biopharmaceuticals Co., Ltd., Sucampo AG, Synergy Pharmaceuticals, Inc., and Synthetic Biologics, Inc. 

By Drug Type

Based on drug types, the global irritable bowel syndrome with constipation drugs market is segmented as follows:

  • Lubiprostone
  • Linaclotide
  • Stimulant Laxatives - Bisacodyl
  • Osmotic Laxatives
  • Lactulose
  • Polyethylene Glycol

Pipeline Drugs

  • Plecanatide – Pre registration
  • Tenapanor- Phase II
  • SYN-010 – Phase II
  • Relenopride – Phase II

An increase in the adoption of unhealthy dietary habits has led to a rise in the prevalence of irritable bowel syndrome with constipation (IBS-C) which has propelled the demand for IBS-C drugs in the current and forecast period from 2018 to 2026. Lubiprostone, linaclotide, stimulant laxatives, and osmotic laxatives are the major drugs used for IBS-C treatment. Lubiprostone (Amitiza) is an irritable bowel syndrome drug that relieves stomach pain, bloating, and straining and produces softer and more frequent bowel movements in patients suffering from IBS- C. It is indicated for treating IBS-C, in women who are at least 18 years of age.

Linaclotide (Linzess) was approved for IBS-C in August 2012 and is projected to hold maximum market share in the IBS-C drugs market in the forecast period from 2018 to 2026, as it possesses lesser side effects in comparison to lubiprostone. The major side effects associated with lubiprostone are diarrhea and dyspnea. In addition, the anticipated approval of plecanatide (Trulance) within the forecast period could hold a dominant position in the market, affecting the market share of linaclotide.

By Geography

For the purpose of this study, the global Irritable Bowel Syndrome with Constipation Drugs market is categorized into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • The Middle East and Africa (MEA)

IBS is a globally prevalent condition that has currently gained market attraction and is considered for target treatment option. Despite being a common condition, IBS often goes undiagnosed until severe. However, reporting of IBS is higher in developed markets. The perpetually growing prevalence of the condition has led to voluntary reporting from patients in North America and Europe. Among the geographies studied, North America dominates the market. The growth is attributed due to the higher prevalence of IBS in this region. As of 2017, according to the FDA, IBS affected about 15.3 Mn people in the United States. Additionally, constant R&D activities and developed healthcare infrastructure also facilitate the growth of this market. For instance, the anticipated approval of the drug plecanatide (Trulance) for IBS-C in the United States by the FDA will further propel the growth of IBS-C drugs market in this region.

IBS-C drugs market in Europe has a wide scope as the region has a substantial prevalence of IBS. Amitiza and Linzess are the two most popular drugs offered in Europe. In addition, a novel option, linaclotide, is already available in the European market under the brand name Constella. However, limited treatment availability in lesser-developed regions such as the Asia Pacific, and poorly tapped market opportunities in these regions where the need is significant, and additional complications from varied lifestyle-related disorders are some of the factors that hold back the growth of the IBS-C drugs market.

By Prescription Type

Based on prescription type, the global irritable bowel syndrome with constipation drugs market is segmented as follows:

  • Prescribed Drugs
  • Over-the-Counter Drugs

Over-the-counter drugs majorly dominate the IBS-C drugs market in the current period. The prime reason for the dominance of this segment is attributed to the increase in the availability of over-the-counter drugs and the lack of consideration of IBS-C as a syndrome thus, the need for approaching a physician is seldom considered. Lubiprostone, polyethylene glycol 3350, and lactulose are some over-the-counter drugs widely used globally. The current therapy for IBS-C majorly involves the consumption of over-the-counter drugs, hence it dominates the IBS-C drugs market. 

Prescription drugs are case-specific and have a potential scope in developed nations. IBS prevalence in North America and Europe is higher as against other regions of the world; this phenomenon, coupled with higher awareness among physicians and the patient population, will lead to the greater number of prescriptions of IBS-C drugs in these regions. The presence of target-based therapy drugs in the pipeline, such as tenapanor, SYN-010 and relenopride, are expected to propel the prescription drugs segment growth post-approval thus encapsulating a major share in the IBS-C drugs market. Additionally, plecanatide (Trulance) by Synergy Pharmaceuticals is filed for NDA for IBS-C indication (2017). The approval of this product is expected to contribute to the prescription drugs market share during the forecast period from 2018 to 2026.

Frequently asked questions about the global Seed Potato market

The market for Irritable Bowel Syndrome with Constipation Drugs is expected to reach US$ 2.23 Bn in 2026.

The Irritable Bowel Syndrome with Constipation Drugs market is expected to see significant CAGR growth over the coming years, at 6.2%.

The report is forecasted from 2022-2029

The base year of this report is 2021.

Abbott Laboratories, Inc., Ardelyx. Inc., Astellas Pharma Inc., AstraZeneca Plc., Bayer AG, Fresenius Kabi AG, Ironwood Pharmaceuticals, Inc., Sanofi, SK Biopharmaceuticals Co., Ltd., Sucampo AG, Synergy Pharmaceuticals, Inc., and Synthetic Biologics, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Published Date:  Mar 2016
Category:  Pharmaceuticals
Report ID:   57749
Report Format:   PDF
Pages:   120
Rating:    4.5 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
24/7 Research Support